At that time, Gilead announced it would be combining GS 9350 into a single once-daily pill with its experimental integrase inhibitor, elvitegravir, and Truvada (tenofovir plus emtricitabine). The company also reported it would develop GS 9350 as a stand-alone agent for use with non-Gilead antiretrovirals (ARVs) requiring boosting. The Phase II study of the Quad pill covered in today's press announcement—the actual results of which have not been reported publicly—randomized 71 people who'd never taken ARV therapy before to take the Quad pill or Atripla. The goal was to achieve and sustain a viral load of less than 50 copies after 24 weeks of therapy. Gilead reported the Quad pill was roughly similar to Atripla in terms of efficacy. The company did not include the specific numbers in its release, though it stated a similar number of people in both arms discontinued the drug.